SSB's new US bioanalysis lab open for business

By Staff reporter

- Last updated on GMT

SSB's new US bioanalysis lab open for business
Sartorius Stedim Biotech (SSB) has opened a bioanalysis and biosafety testing laboratory in Boston citing US demand for services provided by its recently acquired division, BioOutsource.

The facility houses technology for Antibody Dependent Cell Cytotoxicity (ADCC), Complement Dependent Cytotoxicity (CDC) and Surface Plasmon Resonance (SPR) assays. It will also provide GMP-compliant in vitro and PCR-based assays for the detection of adventitious agents.

Plans for the laboratory were announced in 2014​ a year after BioOutsource set up a sales office in the US.

SSB bought Glasgow, Scotland-based BioOutsource in April last, citing a desire to add contract testing services.

At the time the BioOutsource CEO Gerry Mackay hinted that being part of a larger organisation would allow the contract research organisation (CRO) to tap into demand in other markets, including the US.

He said: “As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing.”

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars